France Multiplex Assays Market (2026-2031)
The France Multiplex Assays Market was valued at $195.3 Million in 2026 and projected to reach to $281.7 Million by 2031, representing a compound annual growth rate of 7.6%. France's multiplex assays market demonstrates steady expansion within the broader European diagnostic landscape, supported by technological advancements and increasing clinical adoption.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
France Multiplex Assays Market Trends and Insights
- Valued at USD 195.3 million in 2026, France is experiencing steady expansion driven by advances in diagnostic technology and increased adoption of multiplexed testing platforms across clinical laboratories.
- By 2031, France's market is forecast to reach USD 281.7 million, representing a compound annual growth rate of 7.6%. The French healthcare system's emphasis on precision medicine and early disease detection is accelerating demand for multiplex assays.
- France's investment in modernizing laboratory infrastructure and regulatory support for innovative diagnostic solutions are key factors supporting market growth.
- Between 2026 and 2031, France is expected to see heightened adoption in immunoassay, nucleic acid, and protein-based multiplex platforms across hospitals, diagnostic centers, and research institutions. France's market trajectory reflects broader European trends toward integrated diagnostic workflows and cost-effective testing solutions.
- The country's strong pharmaceutical and biotechnology sector further supports the commercialization and uptake of advanced multiplex assay technologies..
Key Market Statistics
- CAGR (2026-2031) 7.6% CAGR
- Market Size, 2026 ~USD 195.3 Million
- Forecast, 2031 ~USD 281.7 Million
- Country France
France Multiplex Assays Market Overview
Market Valuation Growth :
France's multiplex assays market is valued at USD 195.3 million in 2026 and is projected to reach USD 281.7 million by 2031, demonstrating robust expansion in European diagnostic capabilities.
Consistent CAGR Performance :
France's market is growing at a 7.6% CAGR, slightly below the global average of 8.3%, reflecting steady adoption of multiplexed testing platforms across French clinical laboratories and diagnostic centers.
Diagnostic Technology Advancement :
French healthcare institutions are increasingly adopting advanced multiplex assay technologies, driven by improvements in diagnostic accuracy, reduced turnaround times, and enhanced patient outcomes in clinical settings.
European Healthcare Integration :
France positions itself as a key growth segment within European healthcare diagnostics, leveraging strong regulatory frameworks and established laboratory infrastructure to drive multiplex assay adoption.
France Multiplex Assays Market Dynamics
- The market's 7.6% CAGR reflects growing demand for efficient, multiplexed testing solutions that enable simultaneous analysis of multiple biomarkers, improving diagnostic efficiency across French healthcare facilities. By 2031, France's market is expected to reach USD 281.7 million, driven by enhanced laboratory capabilities, rising prevalence of chronic diseases, and increased investment in diagnostic infrastructure.
- French healthcare providers are prioritizing multiplex assays for infectious disease screening, oncology diagnostics, and immunological testing, positioning the country as a significant contributor to European market growth..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- France's multiplex assays market is valued at USD 195.3 million in 2026 and is projected to grow to USD 281.7 million by 2031.
- France is experiencing a 7.6% compound annual growth rate, driven by precision medicine adoption and laboratory modernization.
- France's healthcare system prioritizes early disease detection and integrated diagnostic workflows, supporting multiplex assay demand.
- France's robust pharmaceutical and biotechnology sector accelerates commercialization and clinical adoption of advanced multiplex technologies.
Multiplex Assays Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | NEXT-GENERATION SEQUENCING (NGS) (Technology) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 8.3% from 2026 to 2031 |
| Largest Segment | CONSUMABLES (Product & Service) |
| Market Size Base Year (Billions) | ~USD 7.15 (2026) |
| Revenue Forecast (Billions) | ~USD 10.65 (2031) |
| Segments Covered | Product & Service, Type, Technology, Application, End User |
France Multiplex Assays Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Software & Services
By Type
- Autoimmune Diseases
- Bead-Based Nucleic Acid Assays
- Bead-Based Protein Assays
- Biomarker Discovery & Validation
- Cancer
- Cardiovascular Diseases
- Cell-Based Multiplex Assays
- Drug Discovery & Development
- Infectious Diseases
- Metabolism & Endocrinology Disorders
- Nervous System Disorders
- Nucleic Acid Multiplex Assays
- Other Diseases
- Other Nucleic Acid Assays
- Other Protein Assays
- Planar Nucleic Acid Assays
- Planar Protein Assays
- Protein Multiplex Assays
By Technology
- Flow Cytometry
- Fluorescence Detection
- Luminescence
- Multiplex Real-Time Pcr
- Next-Generation Sequencing (Ngs)
- Other Technologies
By Application
- Clinical Diagnostics
- Research & Development
By End User
- Academic & Research Institutes
- Contract Research Organizations
- Hospitals & Diagnostic Laboratories
- Other End Users
- Pharmaceutical & Biotechnology Companies
FRANCE: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 61.9 | 65.3 | 69.2 | 73.4 | 78 | 83.1 | 88.8 | 95 | 6.6 |
| CONTRACT RESEARCH ORGANIZATIONS | 24.8 | 26.2 | 27.9 | 29.7 | 31.6 | 33.8 | 36.2 | 38.9 | 6.9 |
| HOSPITALS & DIAGNOSTIC LABORATORIES | 66.6 | 71.4 | 76.7 | 82.6 | 89.1 | 96.4 | 104.5 | 113.6 | 8.2 |
| OTHER END USERS | 11 | 11.6 | 12.2 | 12.9 | 13.6 | 14.5 | 15.4 | 16.4 | 6.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 82.3 | 87.9 | 94.1 | 101 | 108.5 | 117 | 126.2 | 136.6 | 7.7 |
| TOTAL | 246.6 | 262.4 | 280.1 | 299.5 | 320.9 | 344.7 | 371.1 | 400.5 | 7.4 |
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers need France-specific market data to assess demand for multiplex assay platforms, identify key laboratory segments, and develop localized go-to-market strategies for French healthcare providers.
- In Vitro Diagnostics (IVD) Companies : IVD firms require detailed France market insights to evaluate commercial opportunities, competitive positioning, and reimbursement scenarios for multiplex assay products in French clinical settings.
- Healthcare Investment Firms : Investors need France-specific valuation data and growth forecasts to evaluate investment opportunities in diagnostic companies, laboratory networks, and healthcare technology providers operating in the French market.
- Clinical Laboratory Networks : Laboratory operators require market intelligence on multiplex assay adoption trends, technology ROI, and competitive dynamics in France to guide capital investment and service expansion decisions.
- Healthcare Consultants & Analysts : Consultants need France-focused market data to support client advisory work, competitive benchmarking, and strategic planning for diagnostic service providers and healthcare organizations.
Key Companies in the France Multiplex Assays Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug product services (oral solid, sterile, specialty dosage),Pharmaceutical development services (early to late-stage),Drug substance services (small-molecule and biologics APIs), |
| NANOSTRING TECHNOLOGIES, INC | United States | Private Company | nCounter instruments (Pro, FLEX, SPRINT),nCounter consumables, CodeSets, and panels,GeoMx DSP systems, |
| BIOCARTIS SA | Belgium | Private Company | Idylla oncology assays (cartridges),Idylla infectious disease assays,Idylla instruments and accessories, |
| IMMUCOR, INC. | United States | Private Company | Transfusion (serology instruments and reagents),Transplant & Molecular (HLA, HPA, HEA assays and systems),Platelet-focused and specialty coagulation products, |
| MAXCYTE, INC | United States | Public Company | ExPERT ATx instruments and related consumables,ExPERT STx instruments and related consumables,ExPERT GTx instruments and related consumables, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Arrays and array consumables, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics – infectious and gastrointestinal diseases,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX assays, |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (VITEK, culture media, BACT/ALERT, VIDAS, ETEST, API),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Industrial applications (GENE-UP, VERIFLOW, BIOBALL, TEMPO, ENDONEXT, CHEMUNEX), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (syringes, needles, catheters, sharps, basic disposables),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, related solutions), |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual/reproductive health assays, |
| MERCK KGAA | Germany | Public Company | Life Science (tools, reagents, bioprocessing, CDMO),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, delivery equipment), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| QUANTERIX CORPORATION | United States | Public Company | HD-X instruments and related assays,SR-X and SP-X instruments and assays,Assay kits, reagents, and antibodies (standalone sales), |
| BIO-TECHNE CORPORATION | United States | Public Company | Protein Sciences (reagents and proteomic tools),Diagnostics and Spatial Biology, |
| SEEGENE INC. | South Korea | Public Company | Respiratory disease detection panels,Gastrointestinal and STI pathogen panels,HPV, TB, and drug-resistance assays, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the life sciences sector.
NANOSTRING TECHNOLOGIES, INC
NanoString Technologies, Inc. is a United States-based private company founded in 2003 with 550 employees focused on life science research tools.
BIOCARTIS SA
Biocartis SA is a Belgian private company founded in 2014 with 500 employees developing molecular diagnostics solutions.
IMMUCOR, INC.
Immucor, Inc. is a United States-based private company founded in 1982 with 1,125 employees providing immunohematology and transfusion diagnostics solutions.
MAXCYTE, INC
MaxCyte, Inc. is a United States-based public company founded in 1998 with 91 employees developing cell engineering technologies.
ILLUMINA, INC.
Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees specializing in DNA sequencing and genetic analysis technologies.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees manufacturing life science research and clinical diagnostics products.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and services globally.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees specializing in in vitro diagnostics.
BIOMéRIEUX
bioMérieux is a French public company founded in 1963 with 14,894 employees developing in vitro diagnostics and microbiology solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees manufacturing medical devices and diagnostics.
QIAGEN N.V.
QIAGEN N.V. is a Netherlands-based public company founded in 1984 with 5,500 employees providing molecular diagnostics and life science research tools.
MERCK KGAA
Merck KGaA is a German public company founded in 1668 with 59,077 employees operating in pharmaceuticals, life sciences, and performance materials.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating diversified businesses including diagnostics and life sciences.
QUANTERIX CORPORATION
Quanterix Corporation is a United States-based public company founded in 2007 with 450 employees developing ultra-sensitive protein detection technologies.
BIO-TECHNE CORPORATION
Bio-Techne Corporation is a United States-based public company founded in 1976 with 3,100 employees providing life science tools and reagents.
SEEGENE INC.
Seegene Inc. is a South Korean public company founded in 2000 with 216 employees specializing in molecular diagnostics and PCR-based testing solutions.
Reasons to Buy this Report
- Market-Specific Sizing Data : Access precise valuation figures for France's multiplex assays market (USD 195.3M in 2026, USD 281.7M in 2031) with country-specific CAGR analysis to inform investment and expansion decisions.
- Competitive Landscape Intelligence : Understand France's position within European diagnostics and identify growth opportunities specific to French clinical laboratories, hospital networks, and diagnostic service providers.
- Technology Adoption Insights : Gain detailed understanding of multiplex assay technology adoption patterns across French healthcare institutions, including barriers, drivers, and implementation timelines for strategic planning.
- Regulatory & Market Environment : Leverage France-specific regulatory insights, reimbursement frameworks, and healthcare infrastructure data to develop compliant market entry and growth strategies.
- Forecast-Driven Strategy : Utilize 5-year market projections and growth trends specific to France to align product development, sales strategies, and resource allocation with anticipated market demand.
Frequently asked questions
What is the current size of France's multiplex assays market?
France's multiplex assays market is valued at USD 195.3 million in 2026 and is expected to grow at a 7.6% CAGR through 2031.
What is the projected market size for France by 2031?
France's multiplex assays market is forecast to reach USD 281.7 million by 2031, representing significant growth from the 2026 baseline.
What factors are driving growth in France's multiplex assays market?
France's market growth is driven by precision medicine adoption, laboratory infrastructure modernization, regulatory support for diagnostics, and increased demand for cost-effective multiplexed testing solutions.
Which segments are most prominent in France's multiplex assays market?
France's market includes immunoassay, nucleic acid, and protein-based multiplex platforms, with adoption across hospitals, diagnostic centers, and research institutions.
How does France's multiplex assays market compare to broader European trends?
France's 7.6% CAGR reflects strong European momentum toward integrated diagnostic workflows, with France's pharmaceutical and biotechnology sector supporting accelerated technology commercialization.
RESEARCH METHODOLOGY
The objective of this study is to analyze key market dynamics, including drivers, opportunities, restraints, and challenges, as well as the strategies of major players. It aims to monitor developments across leading players, including acquisitions, product launches, expansions, agreements, and partnerships. Additionally, the study will examine the competitive landscape of the multiplex assay market by evaluating market participants based on various criteria within the overarching categories of business and product strategy. To estimate the market size, both top-down and bottom-up approaches were employed. The market breakdown and data triangulation methods were used to assess segment and subsegment sizes.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were primarily industry experts from core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. The tiers are as follows: Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
For the global market value, annual revenue figures were calculated using revenue mapping for major product manufacturers and OEMs active in the global multiplex assay market. All major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. Also, the global multiplex assay market was split into various segments and sub-segments:
- List of major players operating in the products market at the regional and/or country level
- Product mapping of various multiplex assay manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from multiplex assay (or the nearest reported business unit/product category)
- Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
- Summation of the market value of all segments/subsegments to arrive at the global multiplex assay market
The data mentioned above was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
Market Size Estimation (Bottom-up & Top-down Approaches)
Data Triangulation
After determining the overall size of the global multiplex assay market using the methodology described above, the market was segmented into several segments and subsegments. The data triangulation and market breakdown procedures were employed, as applicable, to complete the overall market engineering process and obtain exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand- and supply-side participants.
Market Definition
The multiplex assay market comprises analytical testing platforms that enable the qualitative and quantitative assessment of multiple analytes from a single biological sample in a single run. These platforms offer advantages such as reduced testing time, increased automation, and the need for fewer biological samples compared to singleplex assays. The industry encompasses instrumentation, reagents, software, and other services utilized for a wide range of applications globally.
Key Stakeholders
- Manufacturers of multiplex assay products
- Suppliers and distributors of multiplex assay products
- Hospitals
- Diagnostic, clinical, and research laboratories
- Research & development (R&D) companies
- Group purchasing organizations (GPOs)
- Medical research laboratories
- Academic medical centers and universities
- Corporate entities
- Accountable care organizations (ACOs)
- Community centers
- Government institutes
- Market research and consulting firms
- Contract manufacturing organizations (CMOs)
- Contract research organizations (CROs)
- Venture capitalists and investors
Report Objectives
- To define, describe, segment, and forecast the multiplex assay market by product & service, type, technology, application, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiplex assay market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the multiplex assay market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the multiplex assay market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and R&D activities of the leading players in the multiplex assay market
- To benchmark players within the multiplex assay market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
Available customizations:
Based on the given market data, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:
GEOGRAPHIC ANALYSIS
- Further breakdown of the Rest of Europe multiplex assay market into Russia, Switzerland, Denmark, Austria, and others
- Further breakdown of the Rest of Asia Pacific multiplex assay market into South Korea, Taiwan, and others
- Further breakdown of the Rest of Latin America multiplex assay market into Argentina, Colombia, Chile, Ecuador, and others
- Further breakdown of the Southeast Asia multiplex assay market into Malaysia, Singapore, Australia, New Zealand, and others
COMPETITIVE LANDSCAPE ASSESSMENT
- Market Share Analysis, by region (North America and Europe), which provides the market share of the top 3 to 5 key players in the multiplex assay market
- Competitive leadership mapping for established players in the US
Get the Full Multiplex Assays Market Report
Full forecast, segment splits, and company analysis for all Multiplex Assays Market.
- Canada Multiplex Assays Market
- US Multiplex Assays Market
- Germany Multiplex Assays Market
- UK Multiplex Assays Market
- Italy Multiplex Assays Market
- Spain Multiplex Assays Market
- China Multiplex Assays Market
- Japan Multiplex Assays Market
- India Multiplex Assays Market
- Brazil Multiplex Assays Market
- Mexico Multiplex Assays Market
- Rest Of Europe Multiplex Assays Market
- Rest Of Asia Pacific Multiplex Assays Market
- Rest Of Latin America Multiplex Assays Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report